Supporting Publications
Azenosertib (WEE1 Inhibitor)
Phase 1 Results of the WEE1 Inhibitor, Azenosertib, in Combination With Gemcitabine in Adult and Pediatric Patients With Relapsed or Refractory Osteosarcoma
Avutu, V. et. al.
(
2024
)
American Society of Clinical Oncology
The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity With KRASG12C Inhibitors in Multiple KRASG12C Models
Jameson, N. et al.
(
2024
)
American Association for Cancer Research
Cyclin E1 Positive Staining Is Frequent and Independent of Prior Platinum Treatment in High Grade Serous Ovarian Cancer
Harismendy, O. et al.
(
2023
)
American Association for Cancer Research Special Conference: Ovarian Cancer
Correlation of Cyclin E1 Expression and Clinical Outcomes in a Phase 1b Dose-Escalation Study of Azenosertib (ZN-c3), a WEE1 inhibitor, in Combination with Chemotherapy (CT) in Patients (pts) with Platinum-Resistant or Refractory (R/R) Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (EOC)
Liu, et al.
(
2023
)
American Society of Clinical Oncology
Cyclin E1 protein overexpression sensitizes ovarian cancer cells to azenosertib (ZN-c3), a novel, selective and orally bioavailable inhibitor of Wee1
Ma, J. et al.
(
2023
)
American Association for Cancer Research
Tumor Pharmacokinetics, Pharmacodynamics and Efficacy Analysis of WEE1 inhibitor, Azenosertib in Patient- Derived Xenograft Models of Glioblastoma
Patel, S. et al.
(
2023
)
American Association for Cancer Research
Preliminary data from a Phase 1 dose escalation study of ZN-c3 plus gemcitabine in relapsed/refractory osteosarcoma
Avutu, V. et al.
(
2022
)
Connective Tissue Oncology Society
A Phase 1/2 dose escalation and dose expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma
Avutu, V. et al.
(
2022
)
American Society for Clinical Oncology
ZN-c3, a potent and selective Wee1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance
Li, J. et al.
(
2022
)
American Association for Cancer Research
Safety and clinical activity of single-agent ZN-c3, an oral Wee1 inhibitor, in a Phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC)
Meric-Bernstam et al.
(
2022
)
American Association for Cancer Research
BH3 mimetics synergize with the Wee1 inhibitor ZN-c3 by activating caspases which induce DNA damage and degrade key proteins
Izadi, H. et al.
(
2022
)
American Association for Cancer Research
A Phase 1b dose-escalation study of ZN-c3, a Wee1 inhibitor, in combination with chemotherapy (CT) in subjects with platinum-resistant or refractory ovarian, peritoneal or fallopian tube cancer
Pasic, A. et al.
(
2022
)
American Association for Cancer Research
Phase 1b dose-escalation study of ZN-c3, a Wee1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer
Fu, S. et al.
(
2021
)
European Society for Medical Oncology
Pharmacodynamic evidence for Wee1 target engagement in surrogate and tumor tissues from a Phase 1 study of the Wee1 inhibitor ZN-c3
Chalasani, P. et al.
(
2021
)
European Society for Medical Oncology
Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer
Huang, P. et al.
(
2021
)
J. Med. Chem.
Discovery of ZN-c3, a potent Wee1 inhibitor with a differentiated pharmacologic and kinase selectivity profile
Li, J. et al.
(
2021
)
American Association for Cancer Research
ZN-d5 (BCL-2 Inhibitor)
A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor Azenosertib (ZN-c3) in Patients (Pts) With Acute Myeloid Leukemia (AML)
Smith, et al.
(
2023
)
American Society of Clinical Oncology
A Phase 1/2 multi-center dose finding study to assess PK and efficacy of ZN-d5, a novel BCL-2 inhibitor for treatment of subjects with relapsed/refractory AL amyloidosis
Kastritis, E. et al.
(
2022
)
American Society of Hematology
Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models
Izadi, H. et al.
(
2022
)
American Association for Cancer Research
A Phase 1 dose-escalation study of ZN-d5, a BCL-2 inhibitor with improved selectivity, in subjects with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)
Zaucha, J. et al.
(
2021
)
European Society for Medical Oncology
Discovery of ZN-d5, a potent BCL-2 inhibitor with improved selectivity for BCL-2
Pinchman, J. et al.
(
2021
)
European Society for Medical Oncology